Skip to content

Krystal Biotech, Inc. KRYS Ratios & Valuation

FY'25FY'24FY'23FY'22
Profitability
Operating margin41.4%+18.8pp22.6%+245pp-222.6%
Net margin52.6%+21.9pp30.7%+9.1pp21.6%
Returns
Return on equity18.9%+8.6pp10.3%+8.7pp1.7%+26.8pp-25.1%-9.4pp
Return on invested capital24%+12.2pp11.9%+40.1pp-28.3%+17.8pp-46.1%+1.3pp
Efficiency
Asset turnover0.3×0.0×0.3×+0.2×0.1×
Liquidity
Current ratio10×+2.7×7.3×-10.5×17.8×+4.5×13.3×-3.9×
Leverage
Debt-to-equity0.0×0.0×0.0×0.0×
Net debt / EBITDA-2.9×+1.8×-4.7×
Per Share
Book value per share$40.72+28.0%$31.82+13.4%$28.06+37.0%$20.49-23.4%
Valuation
Market capitalization$7.15B+58.7%$4.51B+28.9%$3.49B+71.3%$2.04B+17.1%
Price / earnings34.9×-15.6×50.5×-269×319.7×
Price / sales18.4×+2.9×15.5×-53.4×68.9×
Price / book5.9×+1.1×4.8×+0.3×4.5×+0.6×3.9×+1.0×
EV / EBITDA39.9×-18.3×58.2×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Krystal Biotech, Inc.'s ratios come from?
Every ratio is computed from Krystal Biotech, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.